Oscar Health Bounces 1.16% on $250M Volume Ranking 492nd as Bearish Analysts Clash with Mixed Earnings Outlook

Oscar Health (OSCR) closed 1.16% higher on July 30, 2025, with a trading volume of $0.25 billion, ranking 492nd in market activity. The stock’s recent performance follows a series of analyst actions and earnings-related developments that highlight mixed signals for investors.

Analysts have shifted to a bearish stance, with Baird R W downgrading OSCR from “strong-buy” to “hold” and multiple firms including Wells Fargo and Barclays lowering target prices. The consensus price target now stands at $12.21, below the current price of $14.03. Despite these downgrades, Oscar Health reported stronger-than-expected Q2 earnings in May, with revenue rising 42.2% year-over-year to $3 billion. However, recent consensus estimates for the June 2025 quarter project a non-GAAP loss of $0.90 per share, a 550% decline from the prior-year period, as analysts have revised their estimates downward by 306.25% over the past month.

Institutional ownership of OSCR has seen significant changes, with LRI Investments and Jones Financial Companies increasing stakes during Q1 and Q2 2025. Conversely, insider activity has shown a 27.93% reduction in shares held by director Elbert O. Robinson. These movements reflect divergent views on the company’s near-term prospects amid its ongoing transition from a loss-making entity to a profit-generating business.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day generated a 166.71% return from 2022 to the present, outperforming the benchmark by 137.53%. With a Sharpe ratio of 1.14 and a compound annual growth rate of 31.89%, the approach demonstrated strong risk-adjusted returns over the period.